Showing results (261-270 of 280) with videos related to
Sort By:
Pageof 28
Journal of Viral Hepatitis|June 3, 2022
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patientsGamal Shiha, Reham Soliman, Nabiel N H Mikhail, et al.Journal of the American Society of Nephrology : JASN|August 12, 2015
Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GNMohamad Zaidan, Benjamin Terrier, Agnieszka Pozdzik, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 31, 2022
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvirGuillaume Martin-Blondel, Anne-Geneviève Marcelin, Cathia Soulié, et al.Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.Rheumatology (Oxford, England)|November 9, 2023
Heart and systemic sclerosis-findings from a national cohort studyAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort studyLaurent Lam, Hélène Fontaine, Marc Bourliere, et al.BMC Infectious Diseases|January 28, 2022
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosisGeorges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, et al.Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.Journal of Hepatology|February 28, 2025
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosisPierre Nahon, Clovis Lusivika-Nzinga, Philippe Merle, et al.RMD Open|December 10, 2024
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysisAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.Pageof 28